At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 35 target
Drug / intervention
SHR-1316 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04303988Phase 2RecruitingUpdate OverdueUpdated 23mo ago · Completion was 18mo agoEnrollment Stalled
Long Recruiting
Update Overdue
A Prospective, Single-arm, Single-center, Phase II Clinical Study of Triple-negative Breast Cancer Brain Metastases
In Brief
A Phase 2 clinical trial evaluating SHR-1316, Bevacizumab, and 1 other intervention for Breast Cancer. Currently recruiting, targeting 35 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
Study to assess the effectiveness and safety of SHR 1316, bevacizumab combined with cisplatin/carboplatin for treatment of triple-negative breast cancer brain metastases.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
Collaborators--
Timeline
Phase 2RecruitingOverdue
202120222023202420252026
First PostedMar 2020
Enrollment StartMar 2020
Primary CompletionDec 2024
Study CompletionMay 2025
TodayJul 2026
First PostedMar 11, 2020
Enrollment StartMar 30, 2020
Primary CompletionDec 30, 2024
Study CompletionMay 30, 2025
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 6.3 years ago
Interventions
SHR-1316drug
IV
Bevacizumabdrug
IV
Cisplatin/Carboplatindrug
IV